{"organizations": [], "uuid": "52b38919b7ba8dbff846d3540f7759378f2d98fa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-adaptimmune-therapeutics-reports-q/brief-adaptimmune-therapeutics-reports-quarterly-loss-per-ordinary-share-of-0-05-idUSASC09SE9", "country": "US", "domain_rank": 408, "title": "BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T13:38:00.000+02:00", "replies_count": 0, "uuid": "52b38919b7ba8dbff846d3540f7759378f2d98fa"}, "author": "", "url": "https://www.reuters.com/article/brief-adaptimmune-therapeutics-reports-q/brief-adaptimmune-therapeutics-reports-quarterly-loss-per-ordinary-share-of-0-05-idUSASC09SE9", "ord_in_thread": 0, "title": "BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 15, 2018 / 11:40 AM / Updated 25 minutes ago BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05 Reuters Staff March 15 (Reuters) - Adaptimmune Therapeutics Plc: * ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE * ADAPTIMMUNE THERAPEUTICS PLC QUARTERLY LOSS PER ORDINARY SHARE $0.05 * ADAPTIMMUNE THERAPEUTICS - BELIEVES EXISTING CASH AND CASH EQUIVALENTS, SHORT-TERM DEPOSITS TO FUND CURRENT OPERATING PLAN THROUGH TO EARLY 2020 * ADAPTIMMUNE THERAPEUTICS PLC QUARTERLY REVENUE $4.3 MILLION VERSUS $8.5 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-03-15T13:38:00.000+02:00", "crawled": "2018-03-15T14:11:34.006+02:00", "highlightTitle": ""}